GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Allakos Inc (NAS:ALLK) » Definitions » Degree of Financial Leverage

Allakos (Allakos) Degree of Financial Leverage : 0.11 (As of Mar. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Allakos Degree of Financial Leverage?

Degree of Financial Leverage (DFL) measures the percentage change in EPS for a unit change in Earnings Before Interest and Taxes (EBIT). Allakos's Degree of Financial Leverage for the quarter that ended in Mar. 2024 was 0.11. The higher Degree of Financial Leverage, the more volatile earnings will be.

The industry rank for Allakos's Degree of Financial Leverage or its related term are showing as below:

ALLK's Degree of Financial Leverage is ranked better than
80.48% of 1501 companies
in the Biotechnology industry
Industry Median: 0.96 vs ALLK: 0.11

Allakos Degree of Financial Leverage Historical Data

The historical data trend for Allakos's Degree of Financial Leverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Allakos Degree of Financial Leverage Chart

Allakos Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Degree of Financial Leverage
Get a 7-Day Free Trial 0.66 0.89 0.85 0.56 1.56

Allakos Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Degree of Financial Leverage Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.17 1.23 1.37 1.56 0.11

Competitive Comparison of Allakos's Degree of Financial Leverage

For the Biotechnology subindustry, Allakos's Degree of Financial Leverage, along with its competitors' market caps and Degree of Financial Leverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Allakos's Degree of Financial Leverage Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Allakos's Degree of Financial Leverage distribution charts can be found below:

* The bar in red indicates where Allakos's Degree of Financial Leverage falls into.



Allakos Degree of Financial Leverage Calculation

Allakos's Degree of Financial Leverage for the quarter that ended in Mar. 2024 is calculated as:

Degree of Financial Leverage=% Change in Earnings per Share (Diluted)**/% Change in EBIT
=( -2.46 (Mar. 2024) / -2.42 (Mar. 2023) - 1 )/( -196.732 (Mar. 2024) / -171.824 (Mar. 2023) - 1 )
=0.0165/0.145
=0.11***

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** TTM data of EPS and EBIT was used to calculate Degree of Financial Leverage.
*** Please be aware that the Degree of Financial Leverage calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.


Allakos  (NAS:ALLK) Degree of Financial Leverage Explanation

Degree of Financial Leverage (DFL) is a leverage ratio that measures the sensitivity of a company’s Earnings per Share (EPS) to fluctuations in its operating income, also referred to as Earnings Before Interest and Taxes (EBIT), resulting from adjustments in its capital structure. DFL is an essential tool for companies to assess the appropriate level of debt or financial leverage in their capital structure. When EBIT remains relatively stable, it results in stable earnings and earnings per share. In such cases, the company may consider taking on substantial debt. However, for companies operating in industries with significant fluctuations in EBIT, it is advisable to keep debt at a manageable level.

The higher Degree of Financial Leverage, the more volatile earnings will be. Because interest is a fixed expense, leverage can amplify earnings and EPS. This is beneficial when EBIT is growing, but it can become problematic in tough economic conditions when EBIT is under pressure.

Be Aware

The use of financial leverage varies across different industries and business sectors, and the application of Degree of Financial Leverage (DFL) should be adjusted accordingly.


Allakos Degree of Financial Leverage Related Terms

Thank you for viewing the detailed overview of Allakos's Degree of Financial Leverage provided by GuruFocus.com. Please click on the following links to see related term pages.


Allakos (Allakos) Business Description

Industry
Traded in Other Exchanges
Address
825 Industrial Road, Suite 500, San Carlos, CA, USA, 94070
Allakos Inc is a clinical-stage company developing therapeutic antibodies that selectively target immunomodulatory receptors present on the surface of immune effector cells involved in allergic, inflammatory, and proliferative diseases. The company's lead program, AK002, an antibody that targets Siglec-8, an inhibitory receptor found on eosinophils and mast cells. In preclinical and clinical studies, AK002 has been shown to deplete eosinophils and inhibit mast cells.
Executives
Graham Neil Murray Hamilton director 33 MT. GREEN RD, CROTON ON HUDSON, NEW YORK NY 10520
Everett Rand Sutherland director 29 HARTWELL AVENUE, LEXINGTON MA 02421
Dolca Thomas director C/O PRINCIPIA BIOPHARMA INC., 220 E. GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Paul Edward Walker director 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Daniel Janney director PO BOX 7414, JACKSON WY 83002
Amy L Ladd director INTUITIVE SURGICAL, INC, 1020 KIFER RD, SUNNYVALE CA 94086
Craig A. Paterson officer: Chief Medical Officer ALLAKOS INC., 825 INDUSTRIAL ROAD, SUITE 500, SAN CARLOS CA 94070
Margaret Nell Fitzgerald officer: General Counsel and Secretary ALLAKOS INC., 825 INDUSTRIAL ROAD, SUITE 500, SAN CARLOS CA 94070
Steven P James director C/O OCERA THERAPUETICS, 525 UNIVERSITY AVENUE, SUITE 610, PALO ALTO CA 94301
Adam Tomasi officer: COO, CFO and Secretary ZS PHARMA, INC., 508 WRANGLER DRIVE, SUITE 100, COPPELL TX 75019
Robert Alexander director, officer: President and CEO 508 WRANGLER DRIVE, SUITE 100, COPPELL TX 75019
Harlan Baird Radford officer: Chief Financial Officer C/O EBAY INC., 2145 HAMILTON AVENUE, SAN JOSE CA 95125
Rasmussen Henrik S Md officer: Chief Medical Officer 508 WRANGLER DRIVE, SUITE 100, COPPELL TX 75019
John P Mckearn director, 10 percent owner 5820 NANCY DRIVE, SAN DIEGO CA 92121
Peter A Hudson 10 percent owner 701 COOL SPRINGS BOULEVARD, FRANKLIN TN 37067